Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Operating Income (2020 - 2025)

Gain Therapeutics has reported Operating Income over the past 6 years, most recently at $10.2 million for Q4 2025.

  • Quarterly results put Operating Income at $10.2 million for Q4 2025, up 405.96% from a year ago — trailing twelve months through Dec 2025 was -$4.1 million (up 80.08% YoY), and the annual figure for FY2025 was -$4.1 million, up 80.08%.
  • Operating Income for Q4 2025 was $10.2 million at Gain Therapeutics, up from -$4.8 million in the prior quarter.
  • Over the last five years, Operating Income for GANX hit a ceiling of $10.2 million in Q4 2025 and a floor of -$8.2 million in Q2 2024.
  • Median Operating Income over the past 5 years was -$4.5 million (2022), compared with a mean of -$3.9 million.
  • Biggest five-year swings in Operating Income: plummeted 560.06% in 2021 and later skyrocketed 405.96% in 2025.
  • Gain Therapeutics' Operating Income stood at -$3.2 million in 2021, then tumbled by 42.15% to -$4.6 million in 2022, then grew by 3.38% to -$4.4 million in 2023, then grew by 24.42% to -$3.3 million in 2024, then skyrocketed by 405.96% to $10.2 million in 2025.
  • The last three reported values for Operating Income were $10.2 million (Q4 2025), -$4.8 million (Q3 2025), and -$5.1 million (Q2 2025) per Business Quant data.